MARKET

KDMN

KDMN

Kadmon Holdings
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.590
-0.010
-0.22%
After Hours: 4.660 +0.07 +1.53% 18:05 02/26 EST
OPEN
4.650
PREV CLOSE
4.600
HIGH
4.710
LOW
4.440
VOLUME
2.05M
TURNOVER
--
52 WEEK HIGH
5.73
52 WEEK LOW
2.300
MARKET CAP
787.24M
P/E (TTM)
-7.7468
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Kadmon to Present at Upcoming Investor Conferences
February 24, 2021 (ACCESSWIRE via COMTEX) -- NEW YORK, NY / ACCESSWIRE / February 24, 2021 / Kadmon Holdings, Inc. (NASDAQ:KDMN) today announced that Harlan...
ACCESSWIRE · 4d ago
Graviton Enters into Global Licensing Agreement for ROCK2 Inhibitor from Beijing Tide
and , Feb. 23, 2021 /PRNewswire/ -- Graviton Bioscience Corporation ("Graviton"), a privately held early-stage drug development company founded by Dr. , and Beijing Tide Pharmaceutical Co., Ltd. (Beijing Tide) a subsidiary of Sino Biopharmaceutical Limited...
PR Newswire - PRF · 5d ago
Kadmon Announces Closing of $240 Million Convertible Senior Notes Offering Including Full Exercise of $40 Million Over-Allotment Option
NEW YORK, NY / ACCESSWIRE / February 16, 2021 / Kadmon Holdings, Inc. (Nasdaq:KDMN) today announced the closing of $240 million aggregate principal amount of 3.625% convertible senior notes due 2027 (the "Notes") in a private, overnight offering to qualifi...
ACCESSWIRE · 02/16 21:01
Analysts Offer Insights on Healthcare Companies: Kadmon Holdings (KDMN) and Dynatronics (DYNT)
SmarterAnalyst · 02/12 20:35
Kadmon stock down after pricing $200M convertible debt offering
Kadmon Holdings ([[KDMN]] -8.8%) has priced upsized $200M (from $150M) of 3.625% convertible senior unsecured notes due February 15, 2027 in a private offering.Initial purchaser granted an option to purchase up
Seekingalpha · 02/11 18:04
Kadmon Holdings Prices $200 Million Convertible Senior Notes Offering
MT Newswires · 02/11 15:15
TAP, QLYS among premarket losers
Anchiano Therapeutics (ANCN) -28%.Pulmatrix PULM -21% on direct offering.United States Antimony UAMY -21% on direct offering.Cancer Genetics CGIX -21% on stock offering.BioHiTech Global (BHTG) -15%.Fluidigm FLDM -14% on Q4 earnings; inks distribution deal ...
Seekingalpha · 02/11 13:29
Kadmon Announces Pricing of $200 Million Convertible Senior Notes Offering with 100% Capped Call Transactions
NEW YORK, NY / ACCESSWIRE / February 11, 2021 / Kadmon Holdings, Inc. (Nasdaq:KDMN) today announced the pricing of $200 million aggregate principal amount of 3.
ACCESSWIRE · 02/11 13:00
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of KDMN. Analyze the recent business situations of Kadmon Holdings through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average KDMN stock price target is 12.83 with a high estimate of 25.00 and a low estimate of 8.00.
EPS
Institutional Holdings
Institutions: 208
Institutional Holdings: 167.71M
% Owned: 97.78%
Shares Outstanding: 171.51M
TypeInstitutionsShares
Increased
50
15.34M
New
40
5.44M
Decreased
40
21.01M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-1.05%
Pharmaceuticals & Medical Research
-0.68%
Key Executives
Non-Executive Chairman/Independent Director
Tasos Konidaris
President/Chief Executive Officer/Director
Harlan Waksal
Chief Financial Officer/Executive Vice President
Steven Meehan
Executive Vice President/Chief Compliance Officer/General Counsel/Secretary
Gregory Moss
Executive Vice President
John Ryan
Director
Nancy Miller-Rich
Independent Director
Eugene Bauer
Independent Director
David Cohen
Independent Director
Arthur Kirsch
Independent Director
Cynthia Schwalm
  • Dividends
  • Splits
  • Insider Activity
No Data
About KDMN
Kadmon Holdings, Inc. is an integrated biopharmaceutical company engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of various unmet medical needs. The Company is developing product candidates in a number of indications within autoimmune and fibrotic disease, oncology and genetic diseases. Its product pipeline consists of KD025, Tesevatinib and KD034. The Company's other products include Ribasphere RibaPak, Ribasphere, Qsymia, Tetrabenazine and Valganciclovir. KD025 is an orally available, selective small molecule inhibitor of Rho-associated coiled-coil kinase 2 (ROCK2), a molecular target in multiple autoimmune, fibrotic and neurodegenerative diseases. Tesevatinib is an oral tyrosine kinase inhibitor (TKI) designed to block key molecular drivers of tumor growth, metastases and drug resistance. KD034 is the Company's portfolio of enhanced formulations of trientine hydrochloride for the treatment of Wilson's disease.

Webull offers kinds of Kadmon Holdings Inc stock information, including NASDAQ:KDMN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KDMN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading KDMN stock methods without spending real money on the virtual paper trading platform.